Group B streptococcus (GBS) is a commensal bacterium of the human gastrointestinal and genital tracts. It is a leading cause of neonatal sepsis and meningitis, and has also been recognized as an important pathogen in pregnant women and the elderly. We investigated mechanisms of macrolide and tetracycline resistance in GBS colonizing women in Egypt. A total of 100 isolates were screened using standard antibiotic susceptibility tests. A multiplex PCR assay was used to detect macrolide- and tetracycline-resistance determinants. All isolates were uniformly susceptible to penicillin G, ampicillin, cefotaxime, vancomycin and levofloxacin. The resistance rates to erythromycin, clindamycin, azithromycin, tetracycline and chloramphenicol were 17, 14, 16, 98 and 1 %, respectively. Among the erythromycin-resistant isolates, 82.4 % had constitutive macrolide–lincosamide–streptogramin B (cMLSB) resistance, 5.9 % had inducible MLSB (iMLSB) resistance and 11.8 % had M phenotype resistance. Among the cMLSB phenotypes, 64.3 % of isolates harboured the ermB gene and 35.7 % of isolates harboured none of the investigated macrolide-resistance genes. The single strain expressing the iMLSB phenotype possessed the ermA gene. Of the two strains with the M phenotype, only one possessed the mefA/E gene. Conversely, seven macrolide-sensitive strains (MIC <0.03 µg ml−1) were ermB positive and one macrolide-sensitive strain (MIC <0.03 µg ml−1) harboured mefA/E. Tetracycline resistance was predominantly due to tetM, which was detected alone (83.7 %) or in association with tetL (12.2 %), tetK (1 %) or tetO (1 %). One strain carried tetM associated with both tetL and tetK, and another strain carried tetO alone. The tetO strains were positive for the mefA/E gene, and the tetL and tetK carrier strains harboured the ermB gene. Susceptible strains harbouring but not expressing an antibiotic-resistance gene should be regarded as potentially resistant. These results emphasize the need to monitor the epidemiology of GBS antibiotic resistance in Egypt.
AcikgozZ. C., AlmayanlarE., GamberzadeS., GocerS.2004; Macrolide resistance determinants of invasive and noninvasive group B streptococci in a Turkish hospital. Antimicrob Agents Chemother 48:1410–1412 [View Article][PubMed]
BoswihiS. S., UdoE. E., Al-SweihN.2012; Serotypes and antibiotic resistance in group B streptococcus isolated from patients at the Maternity Hospital, Kuwait. J Med Microbiol 61:126–131 [View Article][PubMed]
CLSI2006aPerformance Standards for Antimicrobial Disk Susceptibility Tests Approved Standard , 9th edn. M2-A9 Wayne, PA: Clinical and Laboratory Standards Institute;
CLSI2006bMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Approved Standard , 7th edn. M7-A7 Wayne, PA: Clinical and Laboratory Standards Institute;
De MouyD., CavalloJ. D., LeclercqR., FabreR.AFICORPI-BIO Network. Association de Formation Continue en Pathologie Infectieuse des Biologistes2001; Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob Agents Chemother 45:2400–2402 [View Article][PubMed]
DinerE. J., HayesC. S.2009; Recombineering reveals a diverse collection of ribosomal proteins L4 and L22 that confer resistance to macrolide antibiotics. J Mol Biol 386:300–315 [View Article][PubMed]
Figueira-CoelhoJ., RamirezM., SalgadoM. J., Melo-CristinoJ.2004; Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype distribution, and clonal analysis of macrolide-resistant isolates. Microb Drug Resist 10:31–36 [View Article][PubMed]
FitoussiF., LoukilC., GrosI., ClermontO., MarianiP., BonacorsiS., Le ThomasI., DeforcheD., BingenE.2001; Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother 45:1889–1891 [View Article][PubMed]
HraouiM., Boutiba-Ben BoubakerI., RachdiM., SlimA., Ben RedjebS.2012; Macrolide and tetracycline resistance in clinical strains of Streptococcus agalactiae isolated in Tunisia. J Med Microbiol 61:1109–1113 [View Article][PubMed]
LeclercqR.2002; Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34:482–492 [View Article][PubMed]
PharesC. R., LynfieldR., FarleyM. M., Mohle-BoetaniJ., HarrisonL. H., PetitS., CraigA. S., SchaffnerW., ZanskyS. M.& other authors (2008; Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 299:2056–2065 [View Article][PubMed]
SadowyE., MatyniaB., HryniewiczW.2010; Population structure, virulence factors and resistance determinants of invasive, non-invasive and colonizing Streptococcus agalactiae in Poland. J Antimicrob Chemother 65:1907–1914 [View Article][PubMed]
ShabayekS., AbdallaS., AbouzeidA. M.2014; Serotype and surface protein gene distribution of colonizing group B streptococcus in women in Egypt. Epidemiol Infect 142:208–210[PubMed]
VeraniJ. R., McGeeL., SchragS. J.Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC)2010; Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 59:RR-101–36[PubMed]